BCR and chronic myelogenous leukemia, BCR-ABL1 positive: One of the most promising and successful examples of precision oncology is the treatment of chronic myeloid leukemia (CML) with imatinib.10 The high proportion of the clonal BCR–ABL translocation in CML enabled almost all CML patients to benefit from imatinib.178 Likewise, finding concurrent driver mutations or clonal markers will benefit a large group of people.